NCT01721642已完成1 期
A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASC™) Device During and After Transcatheter Aortic Valve Implantation (TAVI) Procedures
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 31
- 主要终点
- Access safety
研究概览
简要总结
A pilot study to evaluate the safety and efficacy of the Apica Access, Stabilization, and Closure Device for accessing and closing the left ventricular apex during and after Transcatheter Aortic Valve Implantation (TAVI) procedures. Follow-up assessment will be made post-procedure, at 30 days and 90 days as well as longer term follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject age ≥ 18 years of age.
- •Subjects will be selected in accordance with the investigating centers standard operating procedures for TAVI subject selection and treatment. Subjects selected will meet all of the TAVI inclusion criteria as follows:
- •Subject has Senile degenerative aortic stenosis with echocardiography derived criteria: mean gradient > 40 mm Hg or jet velocity > 4.0 m/s or an aortic valve area (AVA) of < 0.8 cm2 (or AVA index < 0.5 cm2/m
- •Subject is symptomatic due to aortic valve stenosis as demonstrated by NYHA Functional Class > II.
- •Additive EuroScore > 9
- •Aortic annulus diameter > 21mm to < 27mm by TEE
- •The subject or the subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.
- •The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.
- •The subject, after formal consults by a cardiologist and two cardiovascular surgeons agreed that medical factors precluding operation, based on a conclusion that the probability of death or serious, irreversible morbidity exceeded the probability of meaningful improvement. Specifically the probability of death or serious, irreversible morbidity exceeded 50%.
排除标准
- •Subjects will be selected in accordance with the investigating centers standard operating procedures for TAVI subject selection and treatment. The following TAVI exclusion criteria shall apply:
- •Evidence of an acute myocardial infarction < 1 month before the intended treatment
- •Aortic valve is a congenital unicuspid or bicuspid valve; or is non-calcified
- •Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation > 3+)
- •Pre-existing prosthetic heart valve in an position, prosthetic ring, or severe (greater than 3+) mitral insufficiency
- •Blood dyscrasias as defined: Leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy.
- •Untreated clinically significant coronary artery disease requiring revascularization
- •Hemodynamic instability requiring inotropic therapy or mechanical hemodynamic support devices
- •Need for emergency surgery for any reason
- •Hypertrophic cardiomyopathy with or without obstruction
- •Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- •Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months
- •A known hypersensitivity of contraindication to asprin, heparin, ticlopidine (Ticlid), or clopidogrel (Plavix), or sensitivity to contrast media, which cannot be adequately pre-medicated
- •Recent (within 6 months) cerebrovascular accident or transient ischemic attack
- •Renal insufficiency and/or end stage renal disease requiring chronic dialysis.
- •Life expectancy < 12 months due to non-cardiac co-morbid conditions.
- •The following ASC device exclusion criteria shall apply:
- •Subjects with <10mm Left ventricular wall thickness at apical access site
- •LVEF < 30%
- •Subject with previous DOR procedure
- •Subject access site has less than 2 cm squared "fat" free area under visual observation
- •Subject has known Allergy or hypersensitivity to Titanium
- •Subject requires MR Imaging post procedure
- •Subject is Pregnant
研究组 & 干预措施
Apica Cardiovascular ASC Device
Experimental
Access, stabilisation and closure with the Apica Cardiovascular ASC Device
干预措施: Apica Cardiovascular ASC Access, Stability and Closure Device (Device)
结局指标
主要结局
Access safety
时间窗: Within 2 hours from initial skin incision
Observation of no myocardial tearing on entry of the device
Closure safety
时间窗: Within 2 hours from initial skin incision
Observation of no acute post-procedural bleeding or pericardial effusion.
次要结局
- Investigational device performance: LV function(24 hours, 30 days and 90 days post-procedure)
研究者
相似试验
已完成
不适用
Tolerance and Efficacy of a Predigested, High Protein, High Omega 3 Fat Enteral Feeding Formula Versus a Standard Formula In Multiple Intensive Care Unit SettingsEnteral FeedingCritical IllnessNCT01448135Columbia University50
已完成
不适用
Light Therapy for Onychomycosis StudyOnychomycosis of ToenailNCT05139888ToeFX Inc.126
终止
1 期
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaGlioblastomaNCT03422094Washington University School of Medicine3
进行中（未招募）
不适用
A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma, non resectableMedDRA version: 9.1Level: LLTClassification code 10033600Term: Pancreatic adenocarcinoma non-resectableEUCTR2006-005104-14-DEniversitätsklinikum Schleswig-Holstein20
进行中（未招募）
不适用
Estudio piloto para evaluar la eficacia y seguridad en las 12 primeras semanas de altas dosis de Ribavirina (1600 mg/día) con apoyo de Epoetina ß (450 UI/kg/semana) en la terapia de inducción en pacientes con hepatitis C coinfectados por el virus de la inmunodeficiencia humana que no respondieron a terapias previas.Hepatitis C crónicaMedDRA version: 9.1Level: LLTClassification code 10019744Term: Hepatitis CMedDRA version: 9.1Level: LLTClassification code 10002725Term: Anti-HIV positiveEUCTR2006-005554-74-ESFundació de LLuita contra la Sida